In which classification would aromatase inhibitors and antiestrogens fall under?

Aromatase inhibitors and antiestrogens are classified as hormonal therapy because they specifically target hormonal pathways that are involved in the growth of certain types of cancers, most notably breast cancer. Aromatase inhibitors work by blocking the conversion of androgens to estrogens, thereby lowering estrogen levels in the body, which can help slow the growth of hormone-sensitive tumors. Antiestrogens, such as tamoxifen, block the action of estrogen at the cellular level, further inhibiting tumor growth.

This classification is distinct from chemotherapy, which involves the use of cytotoxic drugs to kill cancer cells or inhibit their proliferation directly. Targeted therapy, on the other hand, involves drugs that target specific molecular markers or pathways associated with cancer cell growth, which is not the primary focus of either aromatase inhibitors or antiestrogens.

Thus, the correct categorization as hormonal therapy reflects the mechanism of action and therapeutic intent behind these treatments, differentiating them from other modalities like chemotherapy and targeted therapy.